Sign in to our library of over $5 million worth of researchclose

Two Quick Steps

* Required Fields

Click Your Industry



Registered Customers

If you have an account with us, please log in.

* Required Fields



Subscribe today
Sign in to our library of over $5 million worth of researchclose

Two Quick Steps

* Required Fields

Click Your Industry



Registered Customers

If you have an account with us, please log in.

* Required Fields



Subscribe today

We deliver Mobile Wallet Market Research and SWOT Analysis from Alternative Energy to Pharmaceuticals and Healthcare Market Research Reports to Digital Media.

Skip to Main Content »

Search Site
Researchers Currently Online:1425

FDA Approves Yervoy (Ipilimumab), First Targeted Melanoma Therapy for Over a Decade


FDA Approves Yervoy (Ipilimumab), First Targeted Melanoma Therapy for Over a Decade

Double click on above image to view full picture

Zoom Out
Zoom In
Additional Information
Price $500.00
Meta Description No
Publisher GlobalData
Date of Report Dec 4, 2011
Quick Overview
FDA Approves Yervoy (Ipilimumab), First Targeted Melanoma Therapy for Over a Decade

Summary

GlobalData’s report, “FDA Approves Yervoy (Ipilimumab), First Targeted Melanoma Therapy for Over a Decade” provides key update on the approval of Yervoy as the first targeted therapy for melanoma.

Scope

- Data and information on the FDA approval of Yervoy as the first targeted therapy for melanoma

Reasons to buy

- Develop understanding about the melanoma and how the approval of Yervoy will bring a paradigm shift in the treatment of melanoma.
Table of Contents
1 Table of Contents
1 Table of Contents 1
2 Summary 1
3 Melanoma Overview 2
3.1 Disease Overview 2
3.2 Epidemiology 2
3.3 Diagnosis 2
4 Current Therapy Options 3
5 Unmet Need 3
6 Drivers and Barriers 3
6.1 Drivers 3
6.2 Barriers 3
7 Yervoy – New Second-Line Therapy for Advanced Metastatic Melanoma 3
7.1 020 Clinical Trial Details 3
7.2 Dosage and Pricing of Yervoy 4
8 Melanoma Market 4
9 Appendix 4
9.1 Methodology 4
9.1.1 Coverage 4
9.1.2 Secondary Research 5
9.1.3 Primary Research 5
9.1.4 Expert Panel Validation 5
9.2 Contact Us 5
9.3 Disclaimer 5




...